Apomorphine for Parkinson's disease: pharmacologic and clinical considerations
Expert Opin Emerg Drugs. 2023 Nov 1:1-7. doi: 10.1080/14728214.2023.2278677. Online ahead of print.ABSTRACTINTRODUCTION: In Parkinson's disease, dopamine depletion in the basal ganglia leads to symptoms including bradykinesia, gait abnormalities, and cognitive impairment. Even with treatment, the disease course leads to decreases in the amount of dopamine produced and released into the synapse. As dopamine production falls and the treatment course is insufficient to match the metabolic supply and demand, acute 'off' periods develop that cause reemergence of symptoms. Apomorphine is used to reverse these 'off' periods and r...
Source: Expert Opinion on Emerging Drugs - November 1, 2023 Category: Drugs & Pharmacology Authors: Maxwell J Wagner Charles P Daniel Connor J Plaisance Grant E Borne Shahab Ahmadzadeh Sahar Shekoohi Alan D Kaye Source Type: research
